FDA Approves Insulin Glargine-yfgn as First Interchangeable Biosimilar Insulin Product for Diabetes
July 29th 2021Insulin glargine-yfgn is the first interchangeable biosimilar product for the treatment of diabetes approved in the United States, which can provide patients with alternative, equally effective options for treating diabetes that could be more cost effective.
Read More
Biktarvy Demonstrates Efficacy, Viral Suppression in Treatment-Naïve Adults With HIV
July 28th 2021A pooled analysis of a 48-week open-label extension of a pair of phase 3 studies found that 99% of patients with HIV who initiated treatment using bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets maintained an undetectable viral load through 4 years of follow-up.
Read More
Women, Black Adults Less Likely to Receive Heart Failure Diagnoses In Primary Care Settings
July 27th 2021According to the investigators, this discrepancy remains even if the individual reported symptoms of heart failure during a routine outpatient health care appointment within the past 6 months.
Read More